Suppr超能文献

在功能性胆绞痛中,胆管括约肌切开术可缓解对括约肌内注射肉毒杆菌毒素无效的胰胆疼痛。

Biliary sphincterotomy resets pancreaticobiliary pain refractory to intrasphincteric Botox injections in functional biliary pain.

作者信息

Menon Shyam, Mathew Ray

机构信息

Department of Gastroenterology, The Royal Wolverhampton NHS Trust, New Cross Hospital, Wednesfield Road, Wolverhampton, WV10 0QP, UK.

出版信息

Indian J Gastroenterol. 2024 Dec 6. doi: 10.1007/s12664-024-01709-9.

Abstract

BACKGROUND

The management of Type III sphincter of Oddi dysfunction or functional biliary pain (FBP) is challenging. A strategy of intermittent intrasphincteric botulinum toxin (Botox) injections into the sphincter of Oddi can alleviate pancreaticobiliary pain. In patients who lose response to intermittent Botox injections, endoscopic biliary sphincterotomy (ES) could potentially reset pain facilitating ongoing management of symptoms.

METHODS

A retrospective review of case notes over a seven-year period (2014-2021) was performed. All patients underwent blood tests, gastroscopy, trans-abdominal ultrasonography, cross-sectional imaging with magnetic resonance cholangiopancreatography (MRCP)/computed tomography (CT) and endoscopic ultrasound (EUS) to rule out alternative causes for their symptoms of pancreaticobiliary pain. A diagnosis of FBP was made in patients with typical post-cholecystectomy pain and normal liver function tests and bile duct size on imaging. Patients with symptomatic FBP underwent intermittent endoscopic Botox injections to the sphincter of Oddi. Patients who lost response to Botox injections underwent ES and were followed up in an outpatient setting to assess response.

RESULTS

One hundred and thirty (128 female, 2 male) patients with FBP underwent a mean of four (2-8) Botox injections over the study period. Of 130 (90%) patients, 117 reported a significant improvement in pain on post procedure review with 81% of patients managing to discontinue opioid medication post procedure. Fifty-one out of 130 (39%) lost response to Botox injections after a median of six (range 5-11) sessions (median eight months between sessions [range 6-18 months]) and continued to have ongoing pancreaticobiliary pain and subsequently underwent biliary ES. Forty-one out of 50 (82%) reported a clinical improvement in their symptoms of pancreaticobiliary pain following ES, with response persisting at follow-up for up to mean of eight (5-15) months and no further hospital attendances due to severe pancreaticobiliary pain.

CONCLUSION

ES can reset pancreaticobiliary pain in FBP once Botox injection therapy to the sphincter of Oddi becomes ineffective and may provide ongoing relief of symptoms.

摘要

背景

Ⅲ型奥迪括约肌功能障碍或功能性胆绞痛(FBP)的治疗具有挑战性。向奥迪括约肌间歇性注射肉毒杆菌毒素(保妥适)的策略可缓解胰胆疼痛。对于对间歇性保妥适注射失去反应的患者,内镜下胆管括约肌切开术(ES)可能会重新调整疼痛,便于持续管理症状。

方法

对7年期间(2014 - 2021年)的病例记录进行回顾性研究。所有患者均接受了血液检查、胃镜检查、经腹部超声检查、磁共振胰胆管造影(MRCP)/计算机断层扫描(CT)横断面成像以及内镜超声检查(EUS),以排除其胰胆疼痛症状的其他病因。对有典型胆囊切除术后疼痛且肝功能检查及影像学检查显示胆管大小正常的患者诊断为FBP。有症状的FBP患者接受向奥迪括约肌间歇性内镜下注射保妥适。对保妥适注射失去反应的患者接受ES治疗,并在门诊进行随访以评估反应。

结果

130例(128例女性,2例男性)FBP患者在研究期间平均接受了4次(2 - 8次)保妥适注射。130例患者中有117例(90%)在术后复查时报告疼痛有显著改善,81%的患者术后成功停用阿片类药物。130例中有51例(39%)在中位6次(范围5 - 11次)注射后(注射间隔中位时间8个月[范围6 - 18个月])对保妥适注射失去反应,持续存在胰胆疼痛,随后接受了胆管ES治疗。50例中有41例(82%)报告ES治疗后胰胆疼痛症状有临床改善,反应在随访中持续长达平均8个月(5 - 15个月),且未因严重胰胆疼痛再次住院。

结论

一旦向奥迪括约肌注射保妥适治疗无效,ES可重新调整FBP患者的胰胆疼痛,并可能持续缓解症状。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验